Auxora
Phase 2Small molecule
Auxora is one of 25 small molecule programs targeting Pneumonia. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Prevacid
TakedaPreclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Mucinex
AAultman Health Foundation
Preclinical
Tylenol
KKenvue Brands
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Auxora
CCalciMedica, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Auxora. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCalciMedica, Inc.